Transcode Therapeutics Inc
RNAZ7.380USD
-0.150-1.99%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
6.15MMarket Cap
LossP/E TTM
More Details of Transcode Therapeutics Inc Company
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.
Transcode Therapeutics Inc Info
Ticker SymbolRNAZ
Company nameTranscode Therapeutics Inc
IPO dateApr 28, 2021
CEOCalais (Philippe P)
Number of employees7
Security typeOrdinary Share
Fiscal year-endApr 28
Address6 Liberty Square
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02109
Phone18573016857
Websitehttps://www.transcodetherapeutics.com/
Ticker SymbolRNAZ
IPO dateApr 28, 2021
CEOCalais (Philippe P)
Company Executives of Transcode Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas A. (Tom) Fitzgerald
Mr. Thomas A. (Tom) Fitzgerald
Chief Financial Officer, Vice President, Director
Chief Financial Officer, Vice President, Director
2.00
--
Dr. Philippe P. Calais, Ph.D.
Dr. Philippe P. Calais, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
1.00
--
Ms. Elizabeth Czerepak
Ms. Elizabeth Czerepak
Independent Director
Independent Director
--
--
Dr. Erik Manting, Ph.D.
Dr. Erik Manting, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel Vlock
Dr. Daniel Vlock
Chief Medical Officer
Chief Medical Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas A. (Tom) Fitzgerald
Mr. Thomas A. (Tom) Fitzgerald
Chief Financial Officer, Vice President, Director
Chief Financial Officer, Vice President, Director
2.00
--
Dr. Philippe P. Calais, Ph.D.
Dr. Philippe P. Calais, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
1.00
--
Ms. Elizabeth Czerepak
Ms. Elizabeth Czerepak
Independent Director
Independent Director
--
--
Dr. Erik Manting, Ph.D.
Dr. Erik Manting, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel Vlock
Dr. Daniel Vlock
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
CK Life Sciences International Holdings, Inc.
9.08%
DRW Securities, LLC
1.28%
The Vanguard Group, Inc.
0.71%
Geode Capital Management, L.L.C.
0.54%
Citi Investment Research (US)
0.17%
Other
88.22%
Shareholders
Shareholders
Proportion
CK Life Sciences International Holdings, Inc.
9.08%
DRW Securities, LLC
1.28%
The Vanguard Group, Inc.
0.71%
Geode Capital Management, L.L.C.
0.54%
Citi Investment Research (US)
0.17%
Other
88.22%
Shareholder Types
Shareholders
Proportion
Corporation
9.08%
Investment Advisor
1.99%
Investment Advisor/Hedge Fund
0.54%
Research Firm
0.28%
Individual Investor
0.14%
Hedge Fund
0.02%
Other
87.95%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
37
40.93K
4.61%
-48.04K
2025Q2
41
77.84K
18.97%
+69.48K
2025Q1
45
80.09K
9.69%
+74.47K
2024Q4
36
155.76K
22.37%
+143.23K
2024Q3
40
10.06K
1.97%
-8.53K
2024Q2
41
8.22K
4.45%
-5.03K
2024Q1
41
12.92K
7.67%
+11.92K
2023Q4
41
826.00
4.24%
+40.00
2023Q3
39
727.00
50.61%
+276.00
2023Q2
40
361.00
37.13%
+105.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
6.54K
0.79%
--
--
Aug 31, 2025
Geode Capital Management, L.L.C.
4.50K
0.54%
+1.15K
+34.37%
Aug 31, 2025
Tracy (Thomas Joseph)
1.25K
0.15%
+1.25K
--
Mar 07, 2025
Tower Research Capital LLC
402.00
0.05%
+347.00
+630.91%
Jun 30, 2025
SBI Securities Co., Ltd.
10.00
0%
-3.00
-23.08%
Jun 30, 2025
BofA Global Research (US)
8.00
0%
+8.00
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Apr 16, 2025
Merger
28→1
Nov 25, 2024
Merger
33→1
Nov 25, 2024
Merger
33→1
Nov 25, 2024
Merger
33→1
Nov 25, 2024
Merger
33→1
Jan 11, 2024
Merger
40→1
Date
Type
Ratio
Apr 16, 2025
Merger
28→1
Nov 25, 2024
Merger
33→1
Nov 25, 2024
Merger
33→1
Nov 25, 2024
Merger
33→1
Nov 25, 2024
Merger
33→1
Jan 11, 2024
Merger
40→1
Jan 11, 2024
Merger
40→1
Jan 11, 2024
Merger
40→1
Jan 11, 2024
Merger
40→1
May 22, 2023
Merger
20→1
View more
FAQs
Who are the top five shareholders of Transcode Therapeutics Inc?
The top five shareholders of Transcode Therapeutics Inc are:
The Vanguard Group, Inc. holds 6.54K shares, accounting for 0.79% of the total shares.
Geode Capital Management, L.L.C. holds 4.50K shares, accounting for 0.54% of the total shares.
Tracy (Thomas Joseph) holds 1.25K shares, accounting for 0.15% of the total shares.
Tower Research Capital LLC holds 402.00 shares, accounting for 0.05% of the total shares.
SBI Securities Co., Ltd. holds 10.00 shares, accounting for 0.00% of the total shares.
The Vanguard Group, Inc. holds 6.54K shares, accounting for 0.79% of the total shares.
Geode Capital Management, L.L.C. holds 4.50K shares, accounting for 0.54% of the total shares.
Tracy (Thomas Joseph) holds 1.25K shares, accounting for 0.15% of the total shares.
Tower Research Capital LLC holds 402.00 shares, accounting for 0.05% of the total shares.
SBI Securities Co., Ltd. holds 10.00 shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of Transcode Therapeutics Inc?
The top three shareholder types of Transcode Therapeutics Inc are:
CK Life Sciences International Holdings, Inc.
DRW Securities, LLC
The Vanguard Group, Inc.
CK Life Sciences International Holdings, Inc.
DRW Securities, LLC
The Vanguard Group, Inc.
How many institutions hold shares of Transcode Therapeutics Inc (RNAZ)?
As of 2025Q3, 37 institutions hold shares of Transcode Therapeutics Inc, with a combined market value of approximately 40.93K, accounting for 4.61% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -14.35%.
What is the biggest source of revenue for Transcode Therapeutics Inc?
In --, the -- business generated the highest revenue for Transcode Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
